SCHEMBL2320065

SCHEMBL2320065

O=C(CN1CCc2nc3ccccc3c(C(=O)N3CCN(CCO)CC3)c2C1)Nc1cccc(-c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.46
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 5/20 0.45
▸ GAA P10253 1/20 0.45
▸ HTT P42858 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ JAK3 P52333 4/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2448599 0.93 ALDH1A1 (0.53) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL3350814 0.91 LMNA (0.46) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2446843 0.88 ALDH1A1 (0.46) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2321274 0.87 MAPT (0.47) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2323215 0.86 ALDH1A1 (0.45) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2443997 0.86 MAPT (0.47) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2316096 0.84 MAPT (0.54) ALDH1A1MAPTLMNAHTTNPSR1
SCHEMBL2319410 0.83 LMNA (0.47) ALDH1A1MAPTLMNAGAAHTT
SCHEMBL2316929 0.83 ALDH1A1 (0.46) ALDH1A1MAPTLMNAHTTNPSR1
SCHEMBL2321530 0.83 LMNA (0.44) ALDH1A1MAPTLMNAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-22 — — US disclosed
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-22 — — US disclosed
EP-2352733-A1 BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN Merck Patent GmbH (DE) 2011-08-10 — — EP disclosed
WO-2010060532-A1 BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN MERCK PATENT GMBH (DE) 2010-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230471-A1 BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN ENPP2, TPX2, TPD52L2 ALDH1A1 4584/4885MAPT 2887/4885LMNA 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback